Search Results - "Bilen, M A"

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders by Boilève, A, Carlo, M I, Barthélémy, P, Oudard, S, Borchiellini, D, Voss, M H, George, S, Chevreau, C, Landman-Parker, J, Tabone, M-D, Chism, D D, Amin, A, Bilen, M A, Bosse, D, Coulomb-L'hermine, A, Su, Xiaoping, Choueiri, T K, Tannir, Nizar M, Malouf, Gabriel G

“…Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The…”
Get full text

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201 by Necchi, A, Pouessel, D, Leibowitz, R, Gupta, S, Fléchon, A, García-Donas, J, Bilen, M A, Debruyne, P R, Milowsky, M I, Friedlander, T, Maio, M, Gilmartin, A, Li, X, Veronese, M L, Loriot, Y

“…Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of…”
Get more information

Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer by Jani, A., Schreibmann, E., Goyal, S., Raghuveer, H., Hershatter, B., Rossi, P.J., Shelton, J.W., Patel, P.R., Xu, K.M., Goodman, M., Master, V., Joshi, S.S., Kucuk, O., Carthon, B., Bilen, M.A., Cooper, S., Fielder, B., Abiodun-ojo, O., Dhere, V.R., Schuster, D.M.

Get full text

Symmetry violation of quantum multifractality: Gaussian fluctuations versus algebraic localization by Bilen, A. M., Georgeot, B., Giraud, O., Lemarié, G., García-Mata, I.

“…Quantum multifractality is a fundamental property of systems such as non-interacting disordered systems at an Anderson transition and many-body systems in…”
Get full text

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial by Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

“…Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the…”
Get full text

Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC) by McGregor, B.A., Lalani, A.-K., Xie, W., Steinharter, J.A., Martini, D.J., Nuzzo, P.V., Martinez Chanza, N., Harshman, L.C., Bilen, M.A., Choueiri, T.K.

Get full text

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Get full text

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Get full text

Symmetry Violation of Quantum Multifractality: Gaussian fluctuations versus Algebraic Localization by Bilen, A. M, Georgeot, B, Giraud, O, Lemarié, G, García-Mata, I

“…Phys. Rev. Research 3, 022023 (2021) Quantum multifractality is a fundamental property of systems such as non-interacting disordered systems at an Anderson…”
Get full text

901OEV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma by Hoimes, C J, Rosenberg, J E, Srinivas, S, Petrylak, D P, Milowsky, M, Merchan, J R, Bilen, M A, Gupta, S, Carret, A-S, Yuan, N, Melhem-Bertrandt, A, Flaig, T

“…Abstract Background Platinum-based chemotherapy remains the standard of care for patients (pts) with locally advanced or metastatic urothelial carcinoma…”
Get full text

986PInitial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours by Campbell, M T, Xie, W, Shah, A Y, Habra, M A, Jimenez, C, Venkatesan, A M, Bubley, G, McKay, R R, Choueiri, T K, McGregor, B A, Killbridge, K L, Mortazavi, A, Bilen, M A

“…Abstract Background Metastatic primary adrenal tumors include those of cortical origin (ACC) and medullary origin (malignant pheochromocytoma/paraganglioma…”
Get full text

879PActivity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC) by McGregor, B A, Lalani, A-K, Xie, W, Steinharter, J A, Martini, D J, Nuzzo, P V, Martinez Chanza, N, Harshman, L C, Bilen, M A, Choueiri, T K

Get full text

910PDEfficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S) by Choueiri, T K, Larkin, J M G, Pal, S K, Motzer, R J, Venugopal, B, Alekseev, B Y, Miyake, H, Gravis, G, Bilen, M A, Chudnovsky, A, Ching, K A, Mariani, M, Robbins, P B, Huang, B, di Pietro, A, Albiges, L

“…Abstract Background Despite advances in clear cell RCC treatment, pts with sRCC have poor prognosis and are more resistant to VEGF-targeted therapy. In JAVELIN…”
Get full text

908PDPrimary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) by Albiges, L, Rini, B I, Haanen, J B A G, Motzer, R J, Kollmannsberger, C K, Negrier, S, Nole, F, Bedke, J, Bilen, M A, Nathan, P, Tomita, Y, Huang, B, Ching, K A, Chudnovsky, A, Robbins, P B, di Pietro, A, Thomaidou, D, Choueiri, T K

“…Abstract Background On the basis of noninferiority outcomes for pts with metastatic disease who received S vs pts who underwent uCN followed by S (Mejean NEJM…”
Get full text

1221PSites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M A, Shabto, J M, Martini, D J, Liu, Y, Lewis, C, Collins, H H, Akce, M, Kissick, H, Carthon, B C, Shaib, W L, Alese, O B, Steuer, C E, Wu, C, Lawson, D H, Kudchadkar, R, Master, V, El-Rayes, B, Ramalingam, S S, Owonikoko, T K, Harvey, R D

Get full text

133PSarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M A, Martini, D J, Shabto, J M, Liu, Y, Khan, A I, Williams, M A, Lewis, C, Collins, H H, Kissick, H, Carthon, B C, Akce, M, Shaib, W L, Alese, O B, Lawson, D H, Kudchadkar, R, El-Rayes, B, Ramalingam, S S, Owonikoko, T K, Harvey, R D, Master, V A

Get full text

Retrospective review of extrapulmonary small cell carcinoma and prognostic factors by Brammer, J. E., Lulla, P. D., Bilen, M. A., Lynch, G. R.

“…Abstract only…”
Get full text

EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective by Wallace, JF, Adair, N, Perez, JR, Hall, T, Bilen, MA, Sussman, M

Get full text

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101] by Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

Get full text

A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer by Bilen, M. A., Liu, D., Mathew, P., Pagliaro, L. C., Logothetis, C., Araujo, J. C., Aparicio, A., Corn, P. G., Hajdenberg, J., Dakhil, S. R., Tu, S.

“…Abstract only…”
Get full text